Empagliflozin (Jardiance) 10 mg: Supply issue resolved

Boehringer Ingelheim advised us of a temporary supply issue for empagliflozin 10 mg tablets (2599694) due to a shipment delay.

7 April 2022: Marked as resolved. 

This situation only affected the Jardiance 10 mg (empagliflozin 10 mg) presentation. There are no supply issues for the other empagliflozin presentations. 

Check the Schedule listing(external link)


We understand that back orders are filled and supplies are available.

We appreciate your patience. The spread of COVID-19 has slowed the supply chain. People are working hard to get keep stock moving. 

COVID-19: Supply chain update

Alternatives to consider 

Should you have a patient who is having trouble filling their prescription for empagliflozin 10 mg over the next 3 weeks, our clinical advice indicates that there is good safety data(external link) to support the following options.

For those patients currently on Jardiance 10 mg whose HBA1c has still not reached target (53 mmol/mol or less), the prescribing clinician may want to consider prescribing, if clinically appropriate:

  1. Jardiance 25mg (empagliflozin 25mg) presentation or
  2. An appropriate Jardiamet (empagliflozin/metformin) presentation

Note: The Special Authority is transferable to all empagliflozin presentations, so the Special Authority number remains the same. 

Who to contact

If you have a question about funding for empagliflozin (with or without metformin), email enquiry@pharmac.govt.nz

If you have questions about the supply of empagliflozin, contact your wholesaler or your supplier representative.